Payment overview · 2025
General Payments
$1,494.26
65 reported records · 12 companies
Healthcare provider profile · identity verified
Boris Khorets, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · BROOKLYN, NY · NPI 1619989514
Verified facts
What the public records show
CMS Open Payments records show Boris Khorets, M.D. received $1,494.26 in general payments during 2025 across 65 reported records.
Aimmune Therapeutics, Inc. accounted for 31.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Eliquis, Farxiga, Jardiance, Linzess, Mounjaro, Nurtec Odt, Otezla, Ozempic, Prolia, Rybelsus, Trelegy Ellipta, Ubrelvy, Veozah, Zenpep.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 687 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported HUMIRA as an associated drug or biological on 1828 records involving 689 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Humira by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 758 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 296 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 129 claims for Ubrelvy by this doctor in 2024.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 362 claims for Zenpep by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OTEZLA as an associated drug or biological on 177267 records involving 48600 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Otezla by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Prolia by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 256 claims for Myrbetriq by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Veozah as an associated drug or biological on 82795 records involving 35863 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Veozah by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 196 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 113 claims for Nexium by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 365 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 729 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 365 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 135 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 157 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 429 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 729 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Nurtec Odt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $474.61 | 31.8% | 17 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $411.01 | 27.5% | 17 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $140.25 | 9.4% | 12 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $92.02 | 6.2% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $91.18 | 6.1% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $66.24 | 4.4% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $63.28 | 4.2% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $51.12 | 3.4% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $32.11 | 2.1% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $26.16 | 1.8% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $23.40 | 1.6% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.88 | 1.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,494.26 | 65 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $474.61 | 17 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $239.01 | 9 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $172.00 | 8 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $134.60 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $112.09 | 11 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $92.02 | 3 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $84.76 | 6 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $69.79 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $69.79 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $63.28 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $51.12 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $47.87 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $47.87 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $40.91 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $32.11 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $28.16 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $26.16 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $26.16 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $23.40 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $22.88 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $21.39 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $21.39 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $18.37 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $18.37 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $18.37 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 687 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 729 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 196 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 365 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 758 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 135 | exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| OTEZLA otezla |
2025 | Otezla | 2024 | 42 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 429 | exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 14 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 55 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 129 | exact normalized | Medicare Part D |
| Veozah veozah |
2025 | Veozah | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 362 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
687 | 123 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | HUMIRA open payments reported associated product |
CMS Open Payments — General Payments 1828 supporting records · 689 recipient NPIs · example record 1201353784 |
Humira · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
758 | 117 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
296 | 49 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
129 | 18 |
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
362 | 52 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | OTEZLA open payments reported associated product |
CMS Open Payments — General Payments 177267 supporting records · 48600 recipient NPIs · example record 1226871616 |
Otezla · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
14 | 12 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
256 | 33 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Veozah open payments reported associated product |
CMS Open Payments — General Payments 82795 supporting records · 35863 recipient NPIs · example record 1238560678 |
Veozah · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
196 | 38 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
113 | 14 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
49 | 17 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
365 | 55 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
729 | 105 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
55 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
365 | 55 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
135 | 29 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
157 | 19 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
429 | 66 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
729 | 105 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 1752 | 330 |
| Metoprolol Succinate | Metoprolol Succinate | 1548 | 275 |
| Amlodipine Besylate | Amlodipine Besylate | 1222 | 229 |
| Diclofenac Sodium | Diclofenac Sodium | 1187 | 174 |
| Atorvastatin Calcium | Atorvastatin Calcium | 937 | 172 |
| Vascepa | Icosapent Ethyl | 845 | 118 |
| Linzess | Linaclotide | 758 | 117 |
| Eliquis | Apixaban | 729 | 105 |
| Metformin Hcl | Metformin Hcl | 711 | 131 |
| Furosemide | Furosemide | 697 | 117 |
| Creon | Lipase/Protease/Amylase | 687 | 123 |
| Omeprazole | Omeprazole | 621 | 117 |
| Levothyroxine Sodium | Levothyroxine Sodium | 617 | 101 |
| Metoprolol Tartrate | Metoprolol Tartrate | 518 | 96 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 511 | 78 |
| Tamsulosin Hcl | Tamsulosin Hcl | 507 | 90 |
| Pantoprazole Sodium | Pantoprazole Sodium | 497 | 99 |
| Clopidogrel | Clopidogrel Bisulfate | 444 | 81 |
| Zolpidem Tartrate | Zolpidem Tartrate | 439 | 89 |
| Allopurinol | Allopurinol | 437 | 78 |
| Ozempic | Semaglutide | 429 | 66 |
| Dexlansoprazole Dr | Dexlansoprazole | 408 | 64 |
| Losartan Potassium | Losartan Potassium | 406 | 92 |
| Escitalopram Oxalate | Escitalopram Oxalate | 403 | 74 |
| Carvedilol | Carvedilol | 378 | 58 |
| Jardiance | Empagliflozin | 365 | 55 |
| Zenpep | Lipase/Protease/Amylase | 362 | 52 |
| Nebivolol Hcl | Nebivolol Hcl | 359 | 55 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 346 | 63 |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 309 | 34 |
| Hydrochlorothiazide | Hydrochlorothiazide | 307 | 63 |
| Famotidine | Famotidine | 305 | 51 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 297 | 79 |
| Synthroid | Levothyroxine Sodium | 296 | 49 |
| Celecoxib | Celecoxib | 295 | 82 |
| Gabapentin | Gabapentin | 269 | 65 |
| Simvastatin | Simvastatin | 261 | 45 |
| Meclizine Hcl | Meclizine Hcl | 259 | 59 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 258 | 33 |
| Myrbetriq | Mirabegron | 256 | 33 |
| Hydralazine Hcl | Hydralazine Hcl | 255 | 47 |
| Clonidine Hcl | Clonidine Hcl | 250 | 48 |
| Lidocaine | Lidocaine | 249 | 46 |
| Fluticasone Propionate | Fluticasone Propionate | 246 | 58 |
| Icosapent Ethyl | Icosapent Ethyl | 245 | 54 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 242 | 67 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 241 | 49 |
| Dexilant | Dexlansoprazole | 236 | 29 |
| Glipizide Er | Glipizide | 232 | 42 |
| Entresto | Sacubitril/Valsartan | 231 | 40 |
| Januvia | Sitagliptin Phosphate | 231 | 33 |
| Montelukast Sodium | Montelukast Sodium | 231 | 46 |
| Ezetimibe | Ezetimibe | 222 | 37 |
| Xarelto | Rivaroxaban | 222 | 25 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 217 | 42 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 216 | 39 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 200 | 48 |
| Lisinopril | Lisinopril | 198 | 41 |
| Farxiga | Dapagliflozin Propanediol | 196 | 38 |
| Meloxicam | Meloxicam | 196 | 53 |
| Azithromycin | Azithromycin | 195 | 170 |
| Nifedipine Er | Nifedipine | 190 | 36 |
| Potassium Chloride | Potassium Chloride | 182 | 29 |
| Clobetasol Propionate | Clobetasol Propionate | 178 | 43 |
| Colchicine | Colchicine | 176 | 45 |
| Ropinirole Hcl | Ropinirole Hcl | 176 | 36 |
| Breo Ellipta | Fluticasone/Vilanterol | 170 | 24 |
| Glipizide | Glipizide | 169 | 31 |
| Atenolol | Atenolol | 165 | 29 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 162 | 36 |
| Ketoconazole | Ketoconazole | 162 | 26 |
| Donepezil Hcl | Donepezil Hcl | 159 | 24 |
| Lorazepam | Lorazepam | 158 | 50 |
| Trulicity | Dulaglutide | 157 | 19 |
| Valsartan | Valsartan | 156 | 42 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 153 | 46 |
| Clonazepam | Clonazepam | 153 | 52 |
| Finasteride | Finasteride | 150 | 30 |
| Pioglitazone Hcl | Pioglitazone Hcl | 146 | 25 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 143 | 24 |
| Alprazolam | Alprazolam | 140 | 33 |
| Dicyclomine Hcl | Dicyclomine Hcl | 140 | 32 |
| Hydrocortisone | Hydrocortisone | 140 | 40 |
| Mounjaro | Tirzepatide | 135 | 29 |
| Ubrelvy | Ubrogepant | 129 | 18 |
| Doxycycline Hyclate | Doxycycline Hyclate | 128 | 102 |
| Ranolazine Er | Ranolazine | 128 | 20 |
| Dapagliflozin | Dapagliflozin Propanediol | 126 | 26 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 126 | 23 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 124 | 21 |
| Ibuprofen | Ibuprofen | 121 | 48 |
| Mupirocin | Mupirocin Calcium | 121 | 20 |
| Chlorthalidone | Chlorthalidone | 115 | 20 |
| Tramadol Hcl | Tramadol Hcl | 114 | 33 |
| Clotrimazole | Clotrimazole | 113 | 29 |
| Nexium | Esomeprazole Magnesium | 113 | 14 |
| Trazodone Hcl | Trazodone Hcl | 112 | 24 |
| Metformin Hcl Er | Metformin Hcl | 111 | 24 |
| Restasis | Cyclosporine | 110 | 14 |
| Diclofenac Potassium | Diclofenac Potassium | 109 | 16 |
| Enalapril Maleate | Enalapril Maleate | 109 | 18 |
| Glimepiride | Glimepiride | 109 | 21 |
| Spironolactone | Spironolactone | 109 | 18 |
| Bystolic | Nebivolol Hcl | 107 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 106 | 17 |
| Nitroglycerin Patch | Nitroglycerin | 106 | 17 |
| Telmisartan | Telmisartan | 104 | 23 |
| Ammonium Lactate | Ammonium Lactate | 101 | 29 |
| Ventolin Hfa | Albuterol Sulfate | 100 | 19 |
| Doxepin Hcl | Doxepin Hcl | 99 | 11 |
| Repatha Sureclick | Evolocumab | 99 | 15 |
| Sertraline Hcl | Sertraline Hcl | 98 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 96 | 18 |
| Labetalol Hcl | Labetalol Hcl | 94 | 14 |
| Methylprednisolone | Methylprednisolone | 91 | 80 |
| Warfarin Sodium | Warfarin Sodium | 90 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 89 | 24 |
| Halobetasol Propionate | Halobetasol Propionate | 88 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 88 | 14 |
| Pregabalin | Pregabalin | 88 | 18 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 87 | 15 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 85 | 13 |
| Febuxostat | Febuxostat | 84 | 15 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 82 | 15 |
| Dutasteride | Dutasteride | 82 | 13 |
| Memantine Hcl | Memantine Hcl | 82 | 13 |
| Procto-Med Hc | Hydrocortisone | 82 | 15 |
| Edarbyclor | Azilsartan Med/Chlorthalidone | 81 | 11 |
| Nitroglycerin | Nitroglycerin | 77 | 26 |
| Mirtazapine | Mirtazapine | 76 | 18 |
| Single Use Swab | Alcohol Antiseptic Pads | 76 | 25 |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 75 | suppressed |
| Nystatin | Nystatin | 75 | 19 |
| Levetiracetam | Levetiracetam | 74 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 74 | 12 |
| Proctozone-Hc | Hydrocortisone | 73 | 19 |
| Tradjenta | Linagliptin | 73 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 73 | 16 |
| Ztlido | Lidocaine | 73 | 18 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 71 | suppressed |
| Ibuprofen-Famotidine | Ibuprofen/Famotidine | 71 | 13 |
| Diclofenac Epolamine | Diclofenac Epolamine | 70 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 70 | 20 |
| Mometasone Furoate | Mometasone Furoate | 69 | 35 |
| Mupirocin | Mupirocin | 69 | 20 |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 68 | 16 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 66 | 57 |
| Propranolol Hcl | Propranolol Hcl | 65 | 12 |
| Levofloxacin | Levofloxacin | 64 | 55 |
| Acyclovir | Acyclovir | 63 | 14 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 63 | 47 |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 59 | suppressed |
| Temazepam | Temazepam | 59 | 21 |
| Torsemide | Torsemide | 59 | 16 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 58 | suppressed |
| Naproxen Sodium Er | Naproxen Sodium | 58 | suppressed |
| Butalbital-Acetaminophen | Butalbital/Acetaminophen | 57 | suppressed |
| Multaq | Dronedarone Hcl | 57 | suppressed |
| Amcinonide | Amcinonide | 56 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 56 | 12 |
| Metolazone | Metolazone | 56 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 55 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 55 | suppressed |
| Ciclopirox | Ciclopirox | 54 | 11 |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 54 | 13 |
| Valacyclovir | Valacyclovir Hcl | 54 | 38 |
| Cyclosporine | Cyclosporine | 53 | 11 |
| Edarbi | Azilsartan Medoxomil | 52 | suppressed |
| Prednisone | Prednisone | 52 | 21 |
| Amiodarone Hcl | Amiodarone Hcl | 51 | 11 |
| Invokana | Canagliflozin | 51 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 51 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 51 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 51 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 50 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 50 | suppressed |
| Sucralfate | Sucralfate | 50 | 11 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 49 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 49 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 49 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 49 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 49 | 17 |
| Trulance | Plecanatide | 49 | suppressed |
| Fluconazole | Fluconazole | 48 | 25 |
| Fluocinonide | Fluocinonide | 48 | suppressed |
| Benicar | Olmesartan Medoxomil | 47 | suppressed |
| Bupropion Xl | Bupropion Hcl | 47 | suppressed |
| Crestor | Rosuvastatin Calcium | 47 | suppressed |
| Primidone | Primidone | 46 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 46 | 29 |
| Gemtesa | Vibegron | 45 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 44 | 12 |
| Solifenacin Succinate | Solifenacin Succinate | 44 | suppressed |
| Azor | Amlodipine Bes/Olmesartan Med | 43 | suppressed |
| Loperamide | Loperamide Hcl | 43 | suppressed |
| Otezla | Apremilast | 42 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 41 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 41 | 14 |
| Dihydroergotamine Mesylate | Dihydroergotamine Mesylate | 41 | suppressed |
| Tacrolimus | Tacrolimus | 41 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 40 | 12 |
| Benicar Hct | Olmesartan/Hydrochlorothiazide | 39 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 39 | suppressed |
| Etodolac | Etodolac | 39 | 24 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 39 | 15 |
| Alcohol Pads | Alcohol Antiseptic Pads | 38 | 14 |
| Alcohol Swabs | Alcohol Antiseptic Pads | 38 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 38 | suppressed |
| Digoxin | Digoxin | 37 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 37 | suppressed |
| Repaglinide | Repaglinide | 37 | suppressed |
| Rivastigmine | Rivastigmine | 37 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 36 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 36 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 36 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 35 | 12 |
| Naproxen Sodium Cr | Naproxen Sodium | 35 | suppressed |
| Sure Comfort Alcohol | Alcohol Antiseptic Pads | 35 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 34 | 16 |
| Sildenafil Citrate | Sildenafil Citrate | 34 | suppressed |
| Silodosin | Silodosin | 34 | suppressed |
| Olanzapine | Olanzapine | 33 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 33 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 33 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 32 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 32 | suppressed |
| Methimazole | Methimazole | 32 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 32 | 11 |
| Procrit | Epoetin Alfa | 32 | suppressed |
| Ursodiol | Ursodiol | 32 | suppressed |
| Zileuton Er | Zileuton | 32 | suppressed |
| Diazepam | Diazepam | 31 | 13 |
| Diltiazem Hcl | Diltiazem Hcl | 31 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 31 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 30 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 30 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 29 | suppressed |
| Brilinta | Ticagrelor | 28 | suppressed |
| Humulin R U-500 Kwikpen | Insulin Regular, Human | 28 | suppressed |
| Mesalamine | Mesalamine | 28 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 27 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 27 | suppressed |
| Alcohol Swab | Alcohol Antiseptic Pads | 26 | suppressed |
| Cilostazol | Cilostazol | 26 | suppressed |
| Clonidine | Clonidine | 26 | suppressed |
| Lactulose | Lactulose | 26 | suppressed |
| Latanoprost | Latanoprost | 26 | suppressed |
| Ofloxacin | Ofloxacin | 26 | 21 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 26 | 24 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 25 | 12 |
| Hydrocortisone Butyrate | Hydrocortisone Butyrate | 25 | suppressed |
| Rybelsus | Semaglutide | 25 | suppressed |
| Ssd | Silver Sulfadiazine | 25 | 19 |
| Xifaxan | Rifaximin | 25 | suppressed |
| Aripiprazole | Aripiprazole | 24 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 24 | suppressed |
| Ciprofloxacin-Dexamethasone | Ciprofloxacin Hcl/Dexameth | 24 | 17 |
| Fluoxetine Hcl | Fluoxetine Hcl | 23 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 23 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 23 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 22 | suppressed |
| Ibsrela | Tenapanor Hcl | 22 | suppressed |
| Lansoprazole | Lansoprazole | 22 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 22 | suppressed |
| Lubiprostone | Lubiprostone | 22 | suppressed |
| Naftifine Hcl | Naftifine Hcl | 22 | suppressed |
| Nadolol | Nadolol | 21 | suppressed |
| Repatha Syringe | Evolocumab | 21 | suppressed |
| Epinephrine | Epinephrine | 20 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 20 | suppressed |
| Tadalafil | Tadalafil | 19 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 18 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 18 | suppressed |
| Cephalexin | Cephalexin | 18 | 15 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 18 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 18 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 18 | suppressed |
| Pioglitazone-Metformin | Pioglitazone Hcl/Metformin Hcl | 18 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 18 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 18 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 17 | suppressed |
| Calcitriol | Calcitriol | 17 | suppressed |
| Nitro-Dur | Nitroglycerin | 17 | suppressed |
| Rapaflo | Silodosin | 17 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 17 | suppressed |
| Bumetanide | Bumetanide | 16 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 16 | suppressed |
| Eszopiclone | Eszopiclone | 16 | suppressed |
| Ibu | Ibuprofen | 16 | suppressed |
| Novolog Flexpen | Insulin Aspart | 16 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 16 | suppressed |
| Veozah | Fezolinetant | 16 | suppressed |
| Avodart | Dutasteride | 15 | suppressed |
| Desonide | Desonide | 15 | suppressed |
| Easy Comfort Pen Needles | Pen Needle, Diabetic | 15 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 15 | suppressed |
| Lipitor | Atorvastatin Calcium | 15 | suppressed |
| Metronidazole | Metronidazole | 15 | suppressed |
| Nabumetone | Nabumetone | 15 | suppressed |
| Dofetilide | Dofetilide | 14 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 14 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 14 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 14 | suppressed |
| Meloxicam | Meloxicam, Submicronized | 14 | suppressed |
| Naproxen-Esomeprazole Mag | Naproxen/Esomeprazole Mag | 14 | suppressed |
| Niacin Er | Niacin | 14 | suppressed |
| Pentoxifylline | Pentoxifylline | 14 | suppressed |
| Prolia | Denosumab | 14 | 12 |
| Tiotropium Bromide | Tiotropium Bromide | 14 | suppressed |
| Zaleplon | Zaleplon | 14 | suppressed |
| Belsomra | Suvorexant | 13 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 13 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 13 | suppressed |
| Dutasteride-Tamsulosin | Dutasteride/Tamsulosin Hcl | 13 | suppressed |
| Eletriptan Hbr | Eletriptan Hydrobromide | 13 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Horizant | Gabapentin Enacarbil | 13 | suppressed |
| Humira | Adalimumab | 13 | suppressed |
| Naproxen | Naproxen | 13 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 13 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 13 | suppressed |
| Praluent Pen | Alirocumab | 13 | suppressed |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Uloric | Febuxostat | 13 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 12 | suppressed |
| Cefpodoxime Proxetil | Cefpodoxime Proxetil | 12 | 12 |
| Divalproex Sodium Er | Divalproex Sodium | 12 | suppressed |
| Glipizide Xl | Glipizide | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Micardis Hct | Telmisartan/Hydrochlorothiazid | 12 | suppressed |
| Mirabegron Er | Mirabegron | 12 | suppressed |
| Steglatro | Ertugliflozin Pidolate | 12 | suppressed |
| Adlarity | Donepezil Hcl | 11 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 11 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 11 | suppressed |
| Felodipine Er | Felodipine | 11 | suppressed |
| Glyburide-Metformin Hcl | Glyburide/Metformin Hcl | 11 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 11 | suppressed |
| Insulin Lispro Protamine Mix | Insulin Lispro Protamin/Lispro | 11 | suppressed |
| Latuda | Lurasidone Hcl | 11 | suppressed |
| Methocarbamol | Methocarbamol | 11 | suppressed |
| Nexlizet | Bempedoic Acid/Ezetimibe | 11 | suppressed |
| Norvasc | Amlodipine Besylate | 11 | suppressed |
| Np Thyroid | Thyroid,pork | 11 | suppressed |
| Oxiconazole Nitrate | Oxiconazole Nitrate | 11 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 11 | suppressed |
| Xanax | Alprazolam | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,494.26 · 65 records | Aimmune Therapeutics, Inc. | ABRYSVO, COMIRNATY, CREON, ELIQUIS, EVENITY, FARXIGA, JARDIANCE, LINZESS, MOUNJARO, NURTEC ODT, NUZYRA, OTEZLA, Ozempic, PREVNAR 20, PROLIA, QULIPTA, REPATHA, Rybelsus, TRELEGY ELLIPTA, UBRELVY, Veozah, Wegovy, ZAVZPRET, ZENPEP, ZEPBOUND | 24 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error